BioCryst Pharmaceuticals (BCRX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and financial position

• Orladeyo, an oral prophylactic for HAE, is expected to exceed $400 million in revenue this year and is on track toward $1 billion, with profitability targeted this year and full-year cash flow positivity by 2026.

• The company is expanding its pipeline, with clinical programs for Netherton syndrome and DME, and maintains a strong financial position with declining royalty rates and manageable debt.

• Ex-U.S. sales currently contribute 11% of global revenue, expected to grow to 20%, with recent provincial approval in Canada enhancing access.

Orladeyo market dynamics and clinical performance

• Orladeyo is the only approved oral prophylactic for HAE, showing strong real-world efficacy with a 91% reduction in attacks over 96 weeks and a 76% reduction in attack severity.

• About 60% of patients remain on therapy, with discontinuations mainly due to lack of efficacy rather than GI side effects, which are now well managed.

• Prescriber confidence is rising, with 52% of allergists and immunologists likely to prescribe Orladeyo, up from 29% in early 2022–2023.

• Patient demographics include 52% switching from other prophylactics, 32% from on-demand therapy, and 17% treatment-naive.

• Retention rates are stable and comparable to injectable prophylactics, with most discontinuations occurring within the first year.

Competitive landscape and growth strategies

• The market is shifting toward prophylactic therapy, now at 70% in the U.S., expected to rise further.

• New competitors are developing less frequent injectable options, but the company expects oral convenience and efficacy to maintain demand.

• Commercial strategy focuses on efficacy, convenience, real-world evidence, and expanding to pediatric patients with an oral granule formulation, with a U.S. filing planned next year.

• The pediatric addressable market is about 500 in the U.S., with potential for a halo effect as families experience benefits.

• Improvements in reimbursement have increased the proportion of paid patients, with optimism about further gains from Medicare changes.